<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39242614</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein.</ArticleTitle><Pagination><StartPage>20579</StartPage><MedlinePgn>20579</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20579</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-71663-1</ELocationID><Abstract><AbstractText>During COVID-19 pandemic, cases of postvaccination infections and restored SARS-CoV-2 virus have increased after full vaccination, which might be contributed to by immune surveillance escape or virus rebound. Here, artificial linear 9-mer human leucocyte antigen (HLA)-restricted UC peptides were designed based on the well-conserved S2 region of the SARS-CoV-2 spike protein regardless of rapid mutation and glycosylation hindrance. The UC peptides were characterized for its effect on immune molecules and cells by HLA-tetramer refolding assay for HLA-binding ability, by HLA-tetramer specific T cell assay for engaged cytotoxic T lymphocytes (CTLs) involvement, by HLA-dextramer T cell assay for B cell activation, by intracellular cytokine release assay for polarization of immune response, Th1 or Th2. The specific lysis activity assay of T cells was performed for direct activation of cytotoxic T lymphocytes by UC peptides. Mice were immunized for immunogenicity of UC peptides in vivo and immunized sera was assay for complement cytotoxicity assay. Results appeared that through the engagement of UC peptides and immune molecules, HLA-I and II, that CTLs elicited cytotoxic activity by recognizing SARS-CoV-2 spike-bearing cells and preferably secreting Th1 cytokines. The UC peptides also showed immunogenicity and generated a specific antibody in mice by both intramuscular injection and oral delivery without adjuvant formulation. In conclusion, a T-cell vaccine could provide long-lasting protection against SARS-CoV-2 either during reinfection or during SARS-CoV-2 rebound. Due to its ability to eradicate SARS-CoV-2 virus-infected cells, a COVID-19 T-cell vaccine might provide a solution to lower COVID-19 severity and long COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yi-Ru</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Vacino Biotech Co., Ltd., 4F, No. 99, Lane 130, Sec 1, Academia Rd., Nangang District, Taipei, 11571, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liou</LastName><ForeName>Chiung-Wen</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Vacino Biotech Co., Ltd., 4F, No. 99, Lane 130, Sec 1, Academia Rd., Nangang District, Taipei, 11571, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>I-Hua</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Vacino Biotech Co., Ltd., 4F, No. 99, Lane 130, Sec 1, Academia Rd., Nangang District, Taipei, 11571, Taiwan, ROC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jia-Ming</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Vacino Biotech Co., Ltd., 4F, No. 99, Lane 130, Sec 1, Academia Rd., Nangang District, Taipei, 11571, Taiwan, ROC. jiaming@vacinobiotech.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000096202">Protein Subunit Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="Y">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="Y">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="Y">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000096202" MajorTopicYN="N">Protein Subunit Vaccines</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>This research was financially supported by Vacino Biotech Co., Ltd. (Taiwan). Vacino Biotech has patents (US 17/726,688, PCT/CN2022/089266, ROC 111115497) concerning the therapeutic compounds used in this study, for which Yi-Ru Lee and Jia-Ming Chang are also the authors of the patents. Yi-Ru Lee, Chiung-Wen Liou, I-Hua Liu, and Jia-Ming Chang are employees of Vacino Biotech Company and belong to this company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>7</Day><Hour>14</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>7</Day><Hour>14</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39242614</ArticleId><ArticleId IdType="pmc">PMC11379847</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-71663-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-71663-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus Disease (COVID-19) Dashboard. In: World Health Organization (2024). https://covid19.who.int. Accessed 02 July 2024.</Citation></Reference><Reference><Citation>Kyriakidis, N. C., L&#xf3;pez-Cort&#xe9;s, A., Gonz&#xe1;lez, E. V., Grimaldos, A. B. &amp; Prado, E. O. SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. npj Vaccines6, 28 (2021). 10.1038/s41541-021-00292-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00292-w</ArticleId><ArticleId IdType="pmc">PMC7900244</ArticleId><ArticleId IdType="pubmed">33619260</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansone, M., Studahl, M., Berg, S., Gissl&#xe9;n, M. &amp; Sundell, N. Severe multisystem inflammatory syndrome (MIS-C/A) after confirmed SARS-CoV-2 infection: A report of four adult cases. Infect. Dis.54, 378&#x2013;383 (2022).10.1080/23744235.2021.2025422</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.2025422</ArticleId><ArticleId IdType="pubmed">35034549</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafie, C. S. et al. Pathogenic connections in post-COVID conditions: What do we know in the large unknown? A narrative review. Viruses14, 1686 (2022). 10.3390/v14081686</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081686</ArticleId><ArticleId IdType="pmc">PMC9413998</ArticleId><ArticleId IdType="pubmed">36016309</ArticleId></ArticleIdList></Reference><Reference><Citation>Abavisani, M. et al. Mutations in SARS-CoV-2 structural proteins: A global analysis. Virol. J.19, 220 (2022). 10.1186/s12985-022-01951-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01951-7</ArticleId><ArticleId IdType="pmc">PMC9759450</ArticleId><ArticleId IdType="pubmed">36528612</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med.387, 86&#x2013;88 (2022). 10.1056/NEJMc2206576</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206576</ArticleId><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, J. et al. Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera. Genes Dis.9, 1290&#x2013;1300 (2022). 10.1016/j.gendis.2021.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2021.11.007</ArticleId><ArticleId IdType="pmc">PMC8639289</ArticleId><ArticleId IdType="pubmed">34877393</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens, D. M., Taubenberger, J. K. &amp; Fauci, A. S. Universal coronavirus vaccines&#x2014;An urgent need. N. Engl. J. Med.386, 297&#x2013;299 (2022). 10.1056/NEJMp2118468</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2118468</ArticleId><ArticleId IdType="pmc">PMC11000439</ArticleId><ArticleId IdType="pubmed">34910863</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry, E. J. &amp; Barouch, D. H. T cell immunity to COVID-19 vaccines. Science377, 821&#x2013;822 (2022). 10.1126/science.add2897</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.add2897</ArticleId><ArticleId IdType="pubmed">35981045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, S., Karuppanan, K. &amp; Subramaniam, G. Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment. J. Med. Virol.94, 4780&#x2013;4791 (2022). 10.1002/jmv.27927</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27927</ArticleId><ArticleId IdType="pmc">PMC9347785</ArticleId><ArticleId IdType="pubmed">35680610</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashishtha, V. et al. Looking to the future: Is a universal coronavirus vaccine feasible?. Expert Rev. Vaccines21, 277&#x2013;280 (2022). 10.1080/14760584.2022.2020107</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2020107</ArticleId><ArticleId IdType="pubmed">34968153</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, L. et al. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Signal Transduct. Target. Ther.8, 197 (2023). 10.1038/s41392-023-01472-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01472-x</ArticleId><ArticleId IdType="pmc">PMC10170451</ArticleId><ArticleId IdType="pubmed">37164987</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol.7, 409&#x2013;424 (2021).10.1038/s41579-021-00573-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah, P., Canziani, G. A., Carter, E. P. &amp; Chaiken, I. The case for S2: The potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic. Front. Immunol.12, 637651 (2021). 10.3389/fimmu.2021.637651</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.637651</ArticleId><ArticleId IdType="pmc">PMC7985173</ArticleId><ArticleId IdType="pubmed">33767706</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, P. G., Keating, R., Hulse-Post, D. J. &amp; Doherty, P. C. Cell-mediated protection in influenza infection. Emerg. Infect. Dis.12, 48&#x2013;54 (2006). 10.3201/eid1201.051237</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1201.051237</ArticleId><ArticleId IdType="pmc">PMC3291410</ArticleId><ArticleId IdType="pubmed">16494717</ArticleId></ArticleIdList></Reference><Reference><Citation>Toor, S. M., Saleh, R., Nair, V. S., Taha, R. Z. &amp; Elkord, E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology162, 30&#x2013;43 (2021). 10.1111/imm.13262</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13262</ArticleId><ArticleId IdType="pmc">PMC7730020</ArticleId><ArticleId IdType="pubmed">32935333</ArticleId></ArticleIdList></Reference><Reference><Citation>Want, M. Y., Bashir, Z. &amp; Najar, R. A. T cell based immunotherapy for cancer: Approaches and strategies. Vaccines (Basel)11, 835 (2023). 10.3390/vaccines11040835</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040835</ArticleId><ArticleId IdType="pmc">PMC10142387</ArticleId><ArticleId IdType="pubmed">37112747</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, S. et al. Antigen recognition determinants of gammadelta T cell receptors. Science308, 252&#x2013;255 (2005). 10.1126/science.1106480</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1106480</ArticleId><ArticleId IdType="pubmed">15821090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyborova, A. et al. &#x3b3;9&#x3b4;2T cell diversity and the receptor interface with tumor cells. J. Clin. Investig.130, 4637&#x2013;4651 (2020). 10.1172/JCI132489</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI132489</ArticleId><ArticleId IdType="pmc">PMC7456241</ArticleId><ArticleId IdType="pubmed">32484803</ArticleId></ArticleIdList></Reference><Reference><Citation>von Massow, G., Oh, S., Lam, A. &amp; Gustafsson, K. Gamma delta T-cells and their involvement in COVID-19 virus infections. Front. Immunol.12, 741218 (2021). 10.3389/fimmu.2021.741218</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.741218</ArticleId><ArticleId IdType="pmc">PMC8586491</ArticleId><ArticleId IdType="pubmed">34777353</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature584, 457&#x2013;464 (2020). 10.1038/s41586-020-2550-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, O.-W. et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine34, 2008&#x2013;2014 (2016). 10.1016/j.vaccine.2016.02.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.02.063</ArticleId><ArticleId IdType="pmc">PMC7115611</ArticleId><ArticleId IdType="pubmed">26954467</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol.23, 186&#x2013;193 (2022). 10.1038/s41590-021-01122-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin, E. T-cell vaccines could top up immunity to COVID, as variants loom large. Nat. Biotechnol.40, 3&#x2013;4 (2022). 10.1038/d41587-021-00025-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41587-021-00025-3</ArticleId><ArticleId IdType="pubmed">34903837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Q. et al. Identification of SARS-CoV-2-specific T cell and its receptor. J. Hematol. Oncol.17, 15 (2024). 10.1186/s13045-024-01537-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-024-01537-6</ArticleId><ArticleId IdType="pmc">PMC10976674</ArticleId><ArticleId IdType="pubmed">38539271</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell185, 847&#x2013;859 (2022). 10.1016/j.cell.2022.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitmann, J. S. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature601, 617&#x2013;622 (2022). 10.1038/s41586-021-04232-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04232-5</ArticleId><ArticleId IdType="pmc">PMC8791831</ArticleId><ArticleId IdType="pubmed">34814158</ArticleId></ArticleIdList></Reference><Reference><Citation>Somogyi, E. et al. A peptide vaccine candidate tailored to individuals&#x2019; genetics mimics the multi-targeted T cell immunity of COVID-19 convalescent subjects. Front. Genet.12, 684152 (2021). 10.3389/fgene.2021.684152</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.684152</ArticleId><ArticleId IdType="pmc">PMC8261158</ArticleId><ArticleId IdType="pubmed">34249101</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature602, 671&#x2013;675 (2022). 10.1038/s41586-021-04389-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y. &amp; Balicer, R. D. SARS-CoV-2 breakthrough infections in vaccinated individuals: Measurement, causes and impact. Nat. Rev. Immunol.22, 57&#x2013;65 (2022). 10.1038/s41577-021-00662-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00662-4</ArticleId><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway, E. COVID rebound is surprisingly common&#x2014;Even without Paxlovid. Nature10.1038/d41586-022-02121-z (2022). 10.1038/d41586-022-02121-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02121-z</ArticleId><ArticleId IdType="pubmed">35953572</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech, M. et al. Remodeling of T cell dynamics during long COVID is dependent on severity of SARS-CoV-2 infection. Front. Immunol.13, 886431 (2022). 10.3389/fimmu.2022.886431</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.886431</ArticleId><ArticleId IdType="pmc">PMC9226563</ArticleId><ArticleId IdType="pubmed">35757700</ArticleId></ArticleIdList></Reference><Reference><Citation>Riou, C. et al. Escape for recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Sci. Transl. Med.14, eabj6824 (2022). 10.1126/scitranslmed.abj6824</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj6824</ArticleId><ArticleId IdType="pmc">PMC9434381</ArticleId><ArticleId IdType="pubmed">34931886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouzbahani, A. K., Kheirandish, F. &amp; Hosseini, S. Z. Design of a multi-epitope-based peptide vaccine against the S and N proteins of SARS-COV-2 using immunoinformatics approach. Egypt. J. Med. Hum. Genet.23, 16 (2022). 10.1186/s43042-022-00224-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43042-022-00224-w</ArticleId><ArticleId IdType="pmc">PMC8813187</ArticleId><ArticleId IdType="pubmed">37521850</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin, E. Pan-coronavirus vaccine pipeline takes form. Nat. Rev. Drug Discov.21, 324&#x2013;326 (2022). 10.1038/d41573-022-00074-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-022-00074-6</ArticleId><ArticleId IdType="pubmed">35440811</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, Y. et al. An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif. Sci. Immunol.10.1126/sciimmunol.abp9962 (2022). 10.1126/sciimmunol.abp9962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abp9962</ArticleId><ArticleId IdType="pmc">PMC9407945</ArticleId><ArticleId IdType="pubmed">35926067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, K. W. et al. SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies. Sci. Transl. Med.14, eabn3715 (2022). 10.1126/scitranslmed.abn3715</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn3715</ArticleId><ArticleId IdType="pubmed">35895836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry, E. J. et al. Letter to FDA&#x2014;T-cell assessment in vaccine studies_4&#x2013;21&#x2013;22_FINAL.pdf. https://drive.google.com/file/d/1OPfStqOnuKAEUkrjfFUouXMjDB_-tnmV/edit (2022).</Citation></Reference><Reference><Citation>Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep. Med.2, 100204 (2021). 10.1016/j.xcrm.2021.100204</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100204</ArticleId><ArticleId IdType="pmc">PMC7837622</ArticleId><ArticleId IdType="pubmed">33521695</ArticleId></ArticleIdList></Reference><Reference><Citation>Agerer, B. et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 + T cell responses. Sci. Immunol.6, eabg6461 (2021). 10.1126/sciimmunol.abg6461</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg6461</ArticleId><ArticleId IdType="pmc">PMC8224398</ArticleId><ArticleId IdType="pubmed">33664060</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamelin, D. J. et al. The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA-supertype dependent manner. Cell Syst.13, 143&#x2013;157 (2022). 10.1016/j.cels.2021.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2021.09.013</ArticleId><ArticleId IdType="pmc">PMC8492600</ArticleId><ArticleId IdType="pubmed">34637888</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavelle, E. C. &amp; Ward, R. W. Mucosal vaccines&#x2014;Fortifying the frontiers. Nat. Rev. Immunol.22, 236&#x2013;250 (2022). 10.1038/s41577-021-00583-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00583-2</ArticleId><ArticleId IdType="pmc">PMC8312369</ArticleId><ArticleId IdType="pubmed">34312520</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, M. W., Moldoveanu, Z., Ogra, P. L. &amp; Mestecky, J. Mucosal immunity in COVID-19: A neglected but critical aspect of SARS-CoV-2 infection. Front. Immunol.11, 611337 (2020). 10.3389/fimmu.2020.611337</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.611337</ArticleId><ArticleId IdType="pmc">PMC7733922</ArticleId><ArticleId IdType="pubmed">33329607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh-Mohamed, S. et al. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol.15, 799&#x2013;808 (2022). 10.1038/s41385-022-00511-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-022-00511-0</ArticleId><ArticleId IdType="pmc">PMC9037584</ArticleId><ArticleId IdType="pubmed">35468942</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyaka, P. N. Inducing mucosal IgA: A challenge for vaccine adjuvants and delivery systems. J. Immunol.199, 9&#x2013;16 (2017). 10.4049/jimmunol.1601775</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601775</ArticleId><ArticleId IdType="pmc">PMC5719502</ArticleId><ArticleId IdType="pubmed">28630108</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin, M. N. &amp; Roni, M. A. Challenges of storage and stability of mRNA-based COVID-19 vaccines. Vaccines (Basel)9, 1033 (2021). 10.3390/vaccines9091033</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9091033</ArticleId><ArticleId IdType="pmc">PMC8473088</ArticleId><ArticleId IdType="pubmed">34579270</ArticleId></ArticleIdList></Reference><Reference><Citation>Millan, C. L. B., Weeratna, R., Krieg, A. M., Siegrist, C.-A. &amp; Davis, H. L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA95, 15553&#x2013;15558 (1998). 10.1073/pnas.95.26.15553</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.26.15553</ArticleId><ArticleId IdType="pmc">PMC28081</ArticleId><ArticleId IdType="pubmed">9861007</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal, B. M., Chang, J. T. &amp; Shevach, E. M. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T-cells in vivo. J. Immunol.164, 5683&#x2013;5688 (2000). 10.4049/jimmunol.164.11.5683</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.11.5683</ArticleId><ArticleId IdType="pubmed">10820244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassan, C. et al. Naturally processed non-canonical HLA-A*02:01 presented peptides. J. Biol. Chem.290, 2593&#x2013;2603 (2015). 10.1074/jbc.M114.607028</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.607028</ArticleId><ArticleId IdType="pmc">PMC4317018</ArticleId><ArticleId IdType="pubmed">25505266</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia-Calle, G. et al. A PBMC-based system to assess human T cell response to influenza vaccine candidates in vitro. Vaccines (Basel)7, 181 (2019). 10.3390/vaccines7040181</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7040181</ArticleId><ArticleId IdType="pmc">PMC6963913</ArticleId><ArticleId IdType="pubmed">31766202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bont&#xe9;, P.-E. et al. Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. Cell Rep.39, 110916 (2022). 10.1016/j.celrep.2022.110916</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.110916</ArticleId><ArticleId IdType="pubmed">35675780</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaer, D., Zheng, M., Ivy, M. T., Zent, R. &amp; Tiriveedhi, V. Methylselenol producing selenocompounds enhance the efficiency of mammaglobin-A peptide vaccination against breast cancer cells. Oncol. Lett.18, 6891&#x2013;6898 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6876340</ArticleId><ArticleId IdType="pubmed">31807192</ArticleId></ArticleIdList></Reference><Reference><Citation>Osada, T. et al. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res.20, 90 (2018). 10.1186/s13058-018-1023-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13058-018-1023-x</ArticleId><ArticleId IdType="pmc">PMC6085609</ArticleId><ArticleId IdType="pubmed">30092835</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>